Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Conditions:   BRAF NP_004324.2:p.V600E;   BRAF V600K Mutation Present;   Thyroid Gland Anaplastic Carcinoma
Interventions:   Drug: Dabrafenib;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Trametinib
Sponsors:   Manisha Shah;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 5, 2019 / by / in
Comments